This interactive face-to-face program equips primary care practitioners with the knowledge, skills, and confidence to test, diagnose, assess, manage, and treat hepatitis B and hepatitis C. Participants will explore evidence-based approaches to clinical management, treatment pathways, and ongoing support for individuals and families, with the goal of improving health outcomes and reducing the burden of viral hepatitis in the community.
Date: Saturday, 4 July 2026
Time: 9:00am – 1:30pm (AWST)
Venue: Aloft Hotel | The Springs, 27 Rowe Ave, Rivervale WA 6103
Learning Outcomes:
On completion of this course and its components, participants will be able to:
- Discuss the impact of stigma and discrimination on people living with, or at risk of, hepatitis C
- Identify indications for testing and how to diagnose hepatitis C infection
- Describe key elements of pre-treatment assessment
- Explain hepatitis C treatment and post-treatment monitoring
- Identify priority populations for hepatitis B testing in Australia
- Interpret hepatitis B serology results.
- Describe the role of primary care in the testing, diagnosis and management of patients with hepatitis B in the community.
Course Components:
- (Optional) Completion of Online Learning Modules: Clinical Foundation of Hepatitis C. If completed, participants will be awarded an addition CPD hour.
- 90-minute hepatitis B session
- 90-minute hepatitis C session
- Post-course survey
Recommended Resources:
- ASHM’s Decision-making in Hepatitis B tool
- ASHM’s Decision-making in Hepatitis C tool
- B Positive: Hepatitis B Guide for Primary Care
- Managing Hepatitis C in Australia
CPD & Endorsement:
Re-endorsement for the 2026-2028 triennium is currently pending with RACGP and ACRRM. This activity may be suitable for self-claiming CPD hours with your professional body. An estimated equivalent of 3 CPD hours and 1 hepatitis B s100 prescriber point applies. A statement of attendance will be provided for full attendees.
Funding:
This activity is funded by the Western Australian Department of Health.
Target Audience:
General practitioners, nurse practitioners, and other health professionals practicing in a primary care setting, including those intending to prescribe s85 direct acting antiviral medication for the treatment of hepatitis C, and those working towards obtaining or maintaining hepatitis B s100 prescriber accreditation.
